| EMR |
Report |
Adjusted EPS |
BEAT |
pred ~$1.71 vs. cons $1.68 |
MEDIUM |
| EMR |
Report |
Revenue |
BEAT |
pred ~$4.85B vs. cons $4.79B |
MEDIUM |
| EMR |
Report |
Adjusted segment EBITDA margin |
BEAT |
pred ~28.3% vs. cons ~28.0% |
MEDIUM |
| EMR |
Guide |
FY2026 Adjusted EPS guidance |
BETTER |
guide ~$6.58 (raised/narrowed within $6.45-6.55 range) vs. cons $6.52 (FY2026) |
MEDIUM |
| EMR |
Guide |
FY2026 underlying sales growth guidance |
UNCHANGED |
guide ~3% vs. cons ~3% (FY2026) |
MEDIUM |
| EMR |
Guide |
Middle East FY2026 sales headwind |
BETTER |
guide ~0.75pt drag vs. prior guide ~1pt (FY2026) |
LOW |
| EMR |
Guide |
Software ACV growth |
BETTER |
guide ~10%+ vs. cons ~9% (FY2026) |
MEDIUM |
| EMR |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.8% |
— |
MEDIUM |
| EMR |
Return |
5-day cumulative residual |
-3.0% (FADE) |
Stock ran ~14% in three weeks into the print (136→154.88) and options/positioning already price a beat-and-raise; a modest EPS/revenue beat plus only an in-line-to-modest FY sales-growth guide (Middle East drag still ~0.75-1pt, China still down mid-single-digits) leaves little room for further upside surprise, so an initial sell-the-news reaction likely extends over the week as sell-side models trim out-period (Q4/FY27) estimates for continued Middle East/China softness even while praising margin execution, producing net negative drift despite the headline beat. |
MEDIUM |